Hepatic drug metabolism and transport in patients with kidney disease
Authors:
- Reginald F. FryeRFReginald F. Frye
- Gary R. MatzkeGMGary R. Matzke
- 1 November 2003
- journal article
- review article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 42 (5) , 906-925
Abstract
No abstract availableKeywords
This publication has 169 references indexed in Scilit:
- Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humansBritish Journal of Clinical Pharmacology, 2003
- Down‐regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediatorsBritish Journal of Pharmacology, 2002
- The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremiaKidney International, 2002
- Mechanisms of Hepatic Transport of Drugs: Implications for Cholestatic Drug ReactionsSeminars in Liver Disease, 2002
- Drugs as P-glycoprotein substrates, inhibitors, and inducersDrug Metabolism Reviews, 2002
- The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†Drug Metabolism Reviews, 2001
- Bioavailability and Kinetics of Cibenzoline in Patients with Normal and Impaired Renal FunctionThe Journal of Clinical Pharmacology, 1991
- Clearance of ceftriaxone in critical care patients with acute renal failureIntensive Care Medicine, 1990
- Disposition of Minoxidil in Patients with Various Degrees of Renal FunctionThe Journal of Clinical Pharmacology, 1989
- Antipyrine metabolite formation and excretion in patients with chronic renal failureEuropean Journal of Clinical Pharmacology, 1985